Infectious disease specialist Poolbeg Pharma has signed a deal with artificial intelligence company CytoReason to provide analysis of data from human challenge studies on influenza.
The project, which is due to commence immediately,could yield new and better treatments for influenza. It is expected to yield results in early 2023.
CytoReason develops computational disease models for efficient drug discovery and development. Five of the world’s top 10 pharma companies use CytoReason’s technology including Pfizer, Sanofi, Merck KGaA and Roche.
Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables us to develop multiple products faster and more cost effectively than the traditional biotech model.
